Targacept (TRGT) Announces TC-6499 Phase 1/2 Missed Primary Endpoint
Tweet Send to a Friend
Targacept (NASDAQ: TRGT) announced top-line results from a Phase 1/2 exploratory study of TC-6499 as a treatment for diabetic gastroparesis ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
